Roche teams with Flare Therapeutics on transcription factorsnews2024-11-12T12:00:35+00:00November 12th, 2024|Endpoints News|
Trace Neuroscience raises $101M for ALS and other neuro conditionsnews2024-11-12T12:00:33+00:00November 12th, 2024|Endpoints News|
GSK acquires Parkinson’s small molecule from Vesaliusnews2024-11-12T11:30:30+00:00November 12th, 2024|Endpoints News|
Yorvipath’s approval showcases biopharma’s interest in rare endocrine disordernews2024-11-11T16:15:06+00:00November 11th, 2024|Endpoints News|
Stephen Squinto’s JPM life sciences team is raising a new fund for later-stage companiesnews2024-11-07T19:51:31+00:00November 7th, 2024|Endpoints News|
Joe Jimenez’s latest Aditum company lines up T cell engager from Chinanews2024-11-07T12:03:51+00:00November 7th, 2024|Endpoints News|
‘We’re good’ on weight loss: Biopharmas turn to muscle with new obesity drugsnews2024-11-06T12:00:14+00:00November 6th, 2024|Endpoints News|
Cerebral to pay nearly $3.7M over controlled substance prescribing practicesnews2024-11-05T19:34:26+00:00November 5th, 2024|Endpoints News|
Ferrum Health CEO: Why AI for medical care adoption has been slownews2024-11-05T12:00:58+00:00November 5th, 2024|Endpoints News|
Q&A: Jade CEO talks about reverse merger and IgAN drugsnews2024-10-31T18:21:33+00:00October 31st, 2024|Endpoints News|
